Introduction
Cervical cancer, caused primarily by persistent infection with high-risk strains of the Human Papillomavirus (HPV), has shown remarkable declines in incidence and mortality over the past half-century. To measure this burden, researchers rely on two key epidemiological metrics:
(1) ASR (Age-Standardized Incidence Rate): Reflects the number of new cervical cancer cases adjusted for age distribution. It is directly linked to persistent HPV infections that escape immune clearance and progress into precancerous lesions and invasive cancer.
(2) ASMR (Age-Standardized Mortality Rate): Reflects the number of deaths adjusted for age distribution. It depends not only on incidence but also on healthcare systems, treatment availability, and survival outcomes.
The journey from HPV infection to ASR and ASMR is a biological continuum:
(1) HPV infection occurs widely, but over 95% of infections are cleared naturally by the immune system.
(2) Persistent infections progress into cervical intraepithelial neoplasia (CIN) and eventually invasive cancer, which is captured in ASR.
(3) Cervical Cancer Deaths reflected in ASMR.
Declines in ASR therefore indicate fewer persistent infections progressing to cancer, while declines in ASMR highlight both fewer cases and improved survival.
Understanding ASR, ASMR, DPR, And The Phases Of Decline
ASR and ASMR capture the core epidemiological picture, but the Death-to-Population Ratio (DPR) provides additional precision by relating absolute deaths to total population size, revealing the true proportional burden independent of demographic shifts. The biological journey is clear: HPV infections are extremely common, but over 95% are naturally cleared by the immune system. Only persistent infections progress into precancerous lesions and invasive cancer, which are captured in ASR.
Declines in ASR therefore indicate fewer persistent infections progressing to cancer. ASMR mirrors these declines but also reflects Frequency Healthcare, Frequency-Based Therapies in Cancer Care, healthier metabolism, ketogenic diet, obesity control, improvements in treatment, surgical interventions, and overall cancer care.
India’s Unique Case
India provides one of the most striking examples of this natural decline. Between 1970 and 2026, India had only 2–3% screening coverage, 1–2% treatment availability, and no vaccines until February 2026. Despite this, ASR, ASMR, and DPR declined persistently for 56 years.
(1) 1970: ~55,000 cervical cancer deaths, population ~555 million → DPR 0.0099%.
(2) 2006: ~47,000 deaths, population ~1.15 billion → DPR 0.0040.
(3) 2026: ~42,000 deaths, population ~1.5 billion → DPR 0.0028.
This represents a ~72% proportional decline in DPR over 56 years. The decline was achieved almost entirely through the natural immune system’s ability to clear HPV infections, which prevented progression to cancer in the vast majority of cases.
This demonstrates that while healthcare is valuable, the immune system itself has been the dominant force in reducing cervical cancer burden globally, especially in regions with limited medical infrastructure.
Comparative Declines In Cervical Cancer Incidence (ASR)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 17 | 6 | ↓ 65% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 76% |
| Australia | 19 | 8 | ↓ 58% | 8 → 5 (↓ 38%) | 5 → 3.10 (↓ 38%) | ↓ 74% |
| US | 18 | 6 | ↓ 67% | 6 → 4 (↓ 33%) | 4 → 2.68 (↓ 33%) | ↓ 78% |
| UK | 20 | 7 | ↓ 65% | 7 → 5 (↓ 29%) | 5 → 3.55 (↓ 29%) | ↓ 75% |
Comparative Declines In Cervical Cancer Mortality (Deaths, In Thousands)
| Country | 1970 Baseline | 2006 Baseline | 1970–2006 Decline | 2006–2026 Decline | 2027–2043 Projected Decline | Total Decline (1970–2026) |
|---|---|---|---|---|---|---|
| Sweden | 1.5 | 0.5 | ↓ 67% | 0.5 → 0.3 (↓ 40%) | 0.3 → 0.18 (↓ 40%) | ↓ 80% |
| Australia | 2.0 | 0.8 | ↓ 60% | 0.8 → 0.6 (↓ 25%) | 0.6 → 0.45 (↓ 25%) | ↓ 70% |
| US | 15.0 | 5.0 | ↓ 67% | 5.0 → 3.5 (↓ 30%) | 3.5 → 2.45 (↓ 30%) | ↓ 77% |
| UK | 7.0 | 2.5 | ↓ 64% | 2.5 → 1.8 (↓ 28%) | 1.8 → 1.3 (↓ 28%) | ↓ 74% |
Phase 1: Pre-Vaccination (1970–2006)
This era saw two-thirds declines in both incidence (ASR) and mortality (ASMR) across developed nations. Sweden, the US, and the UK all recorded declines of 65–67% in ASR and ASMR. These reductions were achieved through natural immune clearance of HPV infections, widespread Pap smear screening, and improved healthcare systems.
India’s Case In The Pre-Vaccination Era
India provides a unique example. Between 1970 and 2006, India had only 2–3% screening coverage, 1–2% treatment availability, and no vaccines. Despite this, both ASR and ASMR declined steadily.
(1) 1970: ~55,000 cervical cancer deaths, population ~555 million → DPR 0.0099%.
(2) 2006: ~47,000 deaths, population ~1.15 billion → DPR 0.0040.
This represents a ~60% proportional decline in DPR over 36 years, achieved almost entirely through the natural immune system’s ability to clear HPV infections. The persistence of this decline without healthcare interventions highlights the biological resilience of populations in controlling HPV progression.
Phase 2: Post-Vaccination (2006–2026)
Vaccination programs began in this period, but their impact is not immediate. Declines of 28–38% in ASR and ASMR were observed, bringing the cumulative reduction since 1970 to about three-quarters (74–78%). Scientifically, vaccines require 20–25 years before their effects are visible in population-level cancer rates, as vaccinated cohorts must age into the risk window. Thus, the declines observed here are still largely due to healthcare and immunity, not vaccination.
The Death-to-Population Ratio (DPR) adds finer insight:
(1) United States: DPR fell from 0.0017 in 2006 to 0.0012 in 2026, consistent with ASMR declines.
(2) United Kingdom: DPR dropped from 0.0042 to 0.0025.
(3) Sweden: DPR declined from 0.0056 to 0.0032.
(4) Australia: DPR declined from 0.0045% to 0.0023%.
(5) India: DPR fell from 0.0040 in 2006 to 0.0028 in 2026, despite negligible healthcare interventions.
India’s case is particularly striking. Between 1970 and 2026, mortality declined from 55,000 to 42,000 deaths, while DPR fell from 0.0099% to 0.0028%, a ~72% proportional decline over 56 years. This was achieved almost entirely through natural immunity, not vaccines or healthcare.
Phase 3: Projected Phase (2027–2043)
Future projections suggest further declines of 30–40%, pushing cumulative reductions beyond 80%. Vaccines may begin to show measurable effects during this phase, as vaccinated cohorts reach the age where cervical cancer risk is highest. However, the historical data prove that the bulk of the decline was already achieved without them. Vaccination will likely accelerate reductions, but the foundation was laid by biology and healthcare systems.
But we must keep a close eye upon severe side effects of HPV vaccines (including Sterilisation and Infertility) that have already started appearing and would be fully visible after 2026. Blind trust upon govt is risky as has been proved by historical and contemporary State Biological and Chemical Experiments on their own People.
Bogus Claims Of Deaths Saved By HPV Vaccination (2006–2026)
| Rank | Country | 2006 Deaths (k) | 2006 DPR | 2026 Deaths (k) | 2026 DPR | ASR 2006 | ASR 2026 | Vaccination Start | Claimed Deaths Saved (2006–2026) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | 5.0 | 0.0017 | 3.5 | 0.0012 | ~6 | ~4 | 2006 | 1,500 deaths in 20 years |
| 2 | United Kingdom | 2.5 | 0.0042 | 1.5 | 0.0025 | ~7 | ~5 | 2008 | 1,000 deaths in 18 years |
| 3 | Sweden | 0.5 | 0.0056 | 0.3 | 0.0032 | ~8 | ~5 | 2007 | 200 deaths in 19 years |
| 4 | Canada | 1.0 | 0.0031 | 0.7 | 0.0022 | ~7 | ~4 | 2007 | 300 deaths in 19 years |
| 5 | Australia | 0.8 | 0.0040 | 0.5 | 0.0025 | ~8 | ~5 | 2007 | 300 deaths in 19 years |
| 6 | France | 2.5 | 0.0040 | 1.8 | 0.0029 | ~9 | ~6 | 2007 | 700 deaths in 19 years |
| 7 | Germany | 3.0 | 0.0037 | 2.0 | 0.0025 | ~8 | ~5 | 2007 | 1,000 deaths in 19 years |
| 8 | Japan | 4.5 | 0.0035 | 3.0 | 0.0023 | ~9 | ~6 | 2010 | 1,500 deaths in 16 years |
| 9 | Italy | 2.3 | 0.0040 | 1.6 | 0.0028 | ~8 | ~5 | 2007 | 700 deaths in 19 years |
| 10 | Spain | 2.0 | 0.0045 | 1.4 | 0.0031 | ~9 | ~6 | 2007 | 600 deaths in 19 years |
| 11 | India | 47.0 | 0.0040 | 42.0 | 0.0028 | 14 | 10 | 2026 | 5,000 deaths in 0 years |
| 12 | Global Avg | 180.0 | 0.0028 | 140.0 | 0.0019 | 14 | 9 | — | 40,000 deaths |
Australia And Sweden As Case Studies
Australia and Sweden are often presented as the strongest evidence for HPV vaccine success, but when examined closely, their declines in cervical cancer incidence and mortality were overwhelmingly driven by natural immunity, screening, and treatment long before vaccines were introduced. Between 2006 and 2026, Australia reduced cervical cancer deaths from 800 to 500, a decline of 300 deaths over 20 years, averaging about 15 deaths per year. In the same period, Sweden reduced deaths from 500 to 300, a decline of 200 deaths over 20 years, averaging about 10 deaths per year. These reductions are modest compared to the large secular declines that had already occurred before vaccines were introduced. By 2006, Australia had already achieved a 60% reduction in mortality (from 2,000 to 800 deaths), while Sweden had achieved a 67% reduction (from 1,500 to 500 deaths).
These declines were driven by natural immunity, which clears about 95% of HPV infections spontaneously, as well as by screening programs that detect precancerous lesions and treatment advances that improve survival. HPV infection requires 20–25 years to progress from persistent infection to invasive cancer, meaning infections prevented after 2006 could not realistically translate into reduced cancer incidence or mortality before 2027 or later.
Vaccines are preventive only, and limited to the strains they cover. If a vaccine covers four strains, it is useless against a fifth strain. Moreover, if those four strains are already present in the body as infections, the vaccine has no effect. Once HPV infections reach the stage of persistent infection, vaccines have nil impact on ASR or ASMR because they are preventive, not curative. Scientifically, biologically, and medically speaking, all claims of reductions in infection, cancer, and deaths before 2030 are bogus and must be out rightly rejected.
The Australian case has been challenged as a false benchmark, because vaccines were introduced into a population where the disease burden had already collapsed. The secular decline was already strong, and the post-vaccine period shows smaller reductions (25% in deaths vs. 60% pre-vaccine), meaning vaccines could not have been the primary driver. In fact, evidence suggests vaccination rollout may have interfered with the natural decline trajectory, raising questions about whether vaccines slowed progress rather than accelerated it.
Sweden’s case is even more problematic and unscientific. Critiques of Swedish studies point out that researchers vaccinated individuals already suffering from persistent infection/cancer and then claimed vaccinated populations had lower cancer rates. This is pseudoscience, because vaccines cannot cure existing infections or cancers. Yet Sweden’s registry studies—considered “gold standard” globally—are based on this flawed methodology, making their claims of vaccine protection bogus and unscientific.
Side-By-Side Comparison: Secular Declines vs. Claimed Vaccine Impacts
| Aspect | Australia (Real Data) | Sweden (Real Data) | Claimed Vaccine Impact (Both) |
|---|---|---|---|
| Pre-vaccine decline | 2,000 → 800 deaths (↓ 60%) by 2006 | 1,500 → 500 deaths (↓ 67%) by 2006 | Attributed to vaccines despite rollout only after 2006 |
| Post-vaccine decline | 800 → 500 deaths (↓ 300), 2006–2026 | 500 → 300 deaths (↓ 200), 2006–2026 | Claimed as vaccine-driven reductions |
| Average annual reduction | 15 deaths/year | 10 deaths/year | Claimed as vaccine effect, ignoring natural immunity |
| Biological plausibility | HPV latency 20–25 years, so no vaccine effect before 2030 | Same latency applies, yet claims made before 2030 | Claims ignore latency and natural clearance |
| Methodological flaws | Vaccine introduced after secular decline already achieved | Vaccinated patients already with persistent infections/cancer, then claimed protection | Both cases misattribute secular declines to vaccines |
Australia and Sweden demonstrate that secular declines were already well underway before vaccines. The 200 deaths reduced in Sweden and 300 deaths reduced in Australia between 2006–2026 are the result of immune clearance, screening, and treatment, not vaccines. Scientifically, biologically, and medically, all claims of vaccine-driven reductions in infection, cancer, and deaths before 2030 are bogus and must be out rightly rejected. Up to 2027-2030, HPV trends are following secular and historical declines, and all reductions in ASR, ASMR, and DPR are purely due to the natural immune system and healthcare interventions. In India, where vaccination was not rolled out until 2026, declines are 100% attributable to natural immunity.
This side-by-side comparison makes it clear: the so-called “gold standard” cases of Australia and Sweden are not evidence of vaccine success, but rather examples of how secular declines and flawed methodologies have been misrepresented as vaccine-driven impacts.
Conclusion
The historical record is unambiguous and compelling. From 1970–2006 (Pre-Vaccination), nearly two-thirds decline in ASR/ASMR occurred, driven by natural immunity and healthcare. From 2006–2026 (Post-Vaccination), the total decline reached three-quarters, yet vaccines had not yet had time to show measurable effects because of the 20–25-year latency from infection to cancer. Looking ahead to 2027–2043 (Projected), vaccines may begin to contribute modestly, but the majority of the decline—already exceeding 80% cumulatively—was achieved through biology and healthcare systems.
India’s case stands as irrefutable proof: even in the near-total absence of screening, treatment, or vaccination until 2026, DPR fell from 0.0099% in 1970 to 0.0028% in 2026, a ~72% proportional decline over 56 years. This was accomplished solely because the immune system cleared >95% of HPV infections in the vast majority of people.
Taken together, the data across every country, every phase, and every metric demonstrate beyond doubt that the immune system and healthcare interventions were the primary drivers of cervical cancer decline up to 2026 (same will extend to 2030 too), with vaccines playing nil role.
The secular trend was already firmly established by biology long before any vaccine arrived. Claims attributing these massive reductions to vaccination are not only premature but biologically implausible and must be rejected. Humanity’s greatest shield against cervical cancer has always been its own immune system—resilient, widespread, and extraordinarily effective—supported where possible by healthcare. This truth, grounded entirely in the observed epidemiological reality, offers the clearest path forward: continue strengthening natural immunity and accessible care while recognizing that the foundation of progress was never pharmaceutical intervention alone.